Together, these mechanisms support the observed superiority of SGLT2 inhibitors in heart failure-related outcomes and GLP-1 RAs in atherosclerotic cardiovascular disease prevention while highlighting the potential for synergistic benefits when used in combination. This evidence concerns the gene GLP1R and heart failure.